Union Acquisition Corp. Announces Date of Extraordinary General Meeting of Shareholders and Record Date

NEW YORK–(BUSINESS WIRE)–Union Acquisition Corp. (NYSE: LTN) (“UAC”), a special purpose
acquisition company, has set the date of its extraordinary general
meeting of shareholders (“extraordinary general meeting”) to vote on the
previously announced business combination with Bioceres, Inc., for
Wednesday, February 27, 2019. The date of the extraordinary general
meeting was previously disclosed in the Pre-Effective Amendment No.1 to
UAC’s Registration Statement on Form S-4, filed with the Securities and
Exchange Commission (“SEC”) on February 7, 2019. The extraordinary
general meeting will be held at 10:00 a.m. local time at the offices of
Arnold & Porter Kaye Scholer LLP, located at 250 West 55th Street
Avenue, New York, New York 10019. The record date for those eligible to
receive notice of and to vote at the extraordinary general meeting is
February 7, 2019 (the “Record Date”). UAC expects to mail its definitive
proxy statement/prospectus and related information regarding the
business combination and the extraordinary general meeting on or about
February 11, 2019.

Ensuring Your Vote is Counted

UAC advises holders of its securities to move their securities into
accounts that do not permit the lending of securities, so called cash
accounts or segregated accounts, and out of accounts that permit the
lending of securities, such as margin accounts. These steps are designed
to ensure that votes related to ordinary shares beneficially owned by
shareholders are properly counted. Beneficial owners of ordinary shares
that have been lent out (either with or without the beneficial owners’
knowledge) are not permitted to vote those shares.

About Union Acquisition Corp.

Union Acquisition Corp. is a blank check company organized for the
purpose of effecting a merger, share exchange, asset acquisition, stock
purchase, recapitalization, reorganization, or other similar business
combination with one or more businesses or entities. UAC’s efforts to
identify a prospective target business are not limited to any particular
industry or geographic region, although the Company has focused on
target businesses located in Latin America. The Company is led by Juan
Sartori, Chairman of the Board of the Company and Chairman and founder
of Union Group International Ltd., and Kyle P. Bransfield, Chief
Executive Officer of the Company and Partner of Atlantic-Pacific
Capital, Inc.

Forward Looking Statements

This communication includes “forward-looking statements” within the
meaning of the “safe harbor” provisions of the United States Private
Securities Litigation Reform Act of 1995. Forward-looking statements may
be identified by the use of words such as “forecast,” “intend,” “seek,”
“target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,”
“outlook,” and “project” and other similar expressions that predict or
indicate future events or trends or that are not statements of
historical matters. Such forward-looking statements include estimated
financial information. Such forward-looking statements with respect to
revenues, earnings, performance, strategies, prospects and other aspects
of the businesses of UAC, Bioceres or the combined company after
completion of the business combination are based on current expectations
that are subject to known and unknown risks and uncertainties, which
could cause actual results or outcomes to differ materially from
expectations expressed or implied by such forward- looking statements.
These factors include, but are not limited to: (1) the occurrence of any
event, change or other circumstances that could give rise to the
termination of the exchange agreement entered into in connection with
the proposed business combination (the “Exchange Agreement”) and the
proposed business combination contemplated therein; (2) the inability to
complete the transactions contemplated by the Exchange Agreement due to
the failure to obtain approval of the shareholders or other conditions
to closing in the Exchange Agreement; (3) the ability of UAC to continue
to meet applicable NYSE listing standards; (4) the risk that the
proposed business combination disrupts current plans and operations of
Bioceres as a result of the announcement and consummation of the
transactions described in the Exchange Agreement; (5) the ability to
recognize the anticipated benefits of the proposed business combination,
which may be affected by, among other things, competition, the ability
of the combined company to grow and manage growth profitably, maintain
relationships with customers and suppliers and retain its management and
key employees; (6) costs related to the proposed business combination;
(7) changes in applicable laws or regulations; (8) the possibility that
Bioceres may be adversely affected by other economic, business, and/or
competitive factors; and (9) other risks and uncertainties indicated
from time to time in the definitive registration statement of UAC in
connection with the proposed business combination and the proxy
statement/prospectus contained therein, including those under “Risk
Factors” therein, and other documents filed or to be filed with the SEC
by UAC. Investors are cautioned not to place undue reliance upon any
forward-looking statements, which speak only as of the date made. UAC
and Bioceres undertake no commitment to update or revise the
forward-looking statements, whether as a result of new information,
future events or otherwise. Investors should carry out their own due
diligence in connection with the assumptions contained herein. The
forward-looking statements in this communication speak only as of the
date of this communication. Although UAC may from time to time
voluntarily update its prior forward-looking statements, it disclaims
any commitment to do so whether as a result of new information, future
events, changes in assumptions or otherwise except as required by
applicable securities laws.

Additional Information and Where to Find It

In connection with the proposed business combination between Bioceres
and UAC, UAC has filed with the SEC a Registration Statement on
Form S-4, a preliminary proxy statement/prospectus and a definitive
proxy statement/prospectus, forming a part thereof. UAC’s shareholders
and other interested persons are advised to read the preliminary proxy
statement/prospectus, and amendments thereto, and the definitive proxy
statement/prospectus in connection with UAC’s solicitation of proxies
for its extraordinary general meeting of shareholders to be held to
approve the proposed business combination because the proxy
statement/prospectus contains important information about the proposed
business combination, UAC and Bioceres. The definitive proxy
statement/prospectus will be mailed to UAC’s shareholders as of the
Record Date on or about February 11, 2019.

Shareholders will also be able to obtain a copy of the preliminary and
definitive Registration Statement, without charge, at the SEC’s website
at http://sec.gov
or by directing a request to: Union Acquisition Corp., 444 Madison
Avenue, Floor 34, New York, NY 10022. UAC shareholders will be able to
obtain free copies of these documents and other documents containing
important information about UAC and Bioceres, once such documents are
filed with the SEC.

No Offer or Solicitation

This announcement is for informational purposes only and is neither an
offer to sell, nor a solicitation of an offer to buy any securities or
the solicitation of any vote in any jurisdiction pursuant to the
proposed transactions or otherwise, nor shall there be any sale,
issuance or transfer of securities in any jurisdiction in which the
offer, solicitation, or sale would be unlawful prior to the registration
or qualification under the securities laws of any such jurisdiction. No
offer of securities shall be made except by means of a prospectus
meeting the requirements of Section 10 of the Securities Act of 1933, as
amended.

Participants in the Solicitation

UAC and its directors, executive officer, certain of its shareholders
prior to its initial public offering and other members of its management
and employees and affiliates, and Bioceres, its directors and management
may be deemed to be participants in the solicitation of proxies from
UAC’s shareholders in connection with the proposed business combination.
Shareholders are urged to carefully read the Registration Statement
regarding the proposed business combination because it contains
important information, including information regarding the persons who
may, under the rules of the SEC, be deemed participants in the
solicitation of UAC’s shareholders in connection with the proposed
business combination, as well as information about UAC’s executive
officers and directors.

Contacts

UAC:
Kyle Bransfield, Chief Executive Officer, UAC
+1
212 981 0633
kbransfield@apcap.com

error: Content is protected !!